BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 25938971)

  • 1. Changing the face of kynurenines and neurotoxicity: therapeutic considerations.
    Bohár Z; Toldi J; Fülöp F; Vécsei L
    Int J Mol Sci; 2015 Apr; 16(5):9772-93. PubMed ID: 25938971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations.
    Tan L; Yu JT; Tan L
    J Neurol Sci; 2012 Dec; 323(1-2):1-8. PubMed ID: 22939820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitochondrial dysfunction related to cell damage induced by 3-hydroxykynurenine and 3-hydroxyanthranilic acid: Non-dependent-effect of early reactive oxygen species production.
    Reyes-Ocampo J; Ramírez-Ortega D; Cervantes GI; Pineda B; Balderas PM; González-Esquivel D; Sánchez-Chapul L; Lugo-Huitrón R; Silva-Adaya D; Ríos C; Jiménez-Anguiano A; Pérez-de la Cruz V
    Neurotoxicology; 2015 Sep; 50():81-91. PubMed ID: 26254737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders.
    Sas K; Robotka H; Toldi J; Vécsei L
    J Neurol Sci; 2007 Jun; 257(1-2):221-39. PubMed ID: 17462670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kynurenines, Parkinson's disease and other neurodegenerative disorders: preclinical and clinical studies.
    Németh H; Toldi J; Vécsei L
    J Neural Transm Suppl; 2006; (70):285-304. PubMed ID: 17017544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain Aging and Disorders of the Central Nervous System: Kynurenines and Drug Metabolism.
    Török N; Majláth Z; Fülöp F; Toldi J; Vécsei L
    Curr Drug Metab; 2016; 17(5):412-29. PubMed ID: 26694727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kynurenine pathway metabolites in humans: disease and healthy States.
    Chen Y; Guillemin GJ
    Int J Tryptophan Res; 2009; 2():1-19. PubMed ID: 22084578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endogenous neurotoxins from tryptophan.
    Stone TW
    Toxicon; 2001 Jan; 39(1):61-73. PubMed ID: 10936623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal Associations of Adherence to the Dietary World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) and Dutch Healthy Diet (DHD) Recommendations with Plasma Kynurenines in Colorectal Cancer Survivors after Treatment.
    Holthuijsen DDB; Bours MJL; Roekel EHV; Breukink SO; Janssen-Heijnen MLG; Keulen ETP; Ueland PM; Midttun Ø; Brezina S; Gigic B; Gsur A; Kok DE; Ose J; Ulrich CM; Weijenberg MP; Eussen SJPM
    Nutrients; 2022 Dec; 14(23):. PubMed ID: 36501181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An expanding range of targets for kynurenine metabolites of tryptophan.
    Stone TW; Stoy N; Darlington LG
    Trends Pharmacol Sci; 2013 Feb; 34(2):136-43. PubMed ID: 23123095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kynurenines in the CNS: from endogenous obscurity to therapeutic importance.
    Stone TW
    Prog Neurobiol; 2001 Jun; 64(2):185-218. PubMed ID: 11240212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Central kynurenine pathway shift with age in women.
    de Bie J; Guest J; Guillemin GJ; Grant R
    J Neurochem; 2016 Mar; 136(5):995-1003. PubMed ID: 26670548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Review on the Role and Function of Cinnabarinic Acid, a "Forgotten" Metabolite of the Kynurenine Pathway.
    Gawel K
    Cells; 2024 Mar; 13(5):. PubMed ID: 38474418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kynurenines in the Pathogenesis of Multiple Sclerosis: Therapeutic Perspectives.
    Biernacki T; Sandi D; Bencsik K; Vécsei L
    Cells; 2020 Jun; 9(6):. PubMed ID: 32604956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitation of Neurotoxic Metabolites of the Kynurenine Pathway by Laser Desorption Ionization Mass Spectrometry (LDI-MS).
    Lahiri P; Dhaware D; Singh A; Panchagnula V; Ghosh D
    Methods Mol Biol; 2019; 1996():113-129. PubMed ID: 31127552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kynurenines in chronic neurodegenerative disorders: future therapeutic strategies.
    Zádori D; Klivényi P; Vámos E; Fülöp F; Toldi J; Vécsei L
    J Neural Transm (Vienna); 2009 Nov; 116(11):1403-9. PubMed ID: 19618107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kynurenines impair energy metabolism in rat cerebral cortex.
    Schuck PF; Tonin A; da Costa Ferreira G; Viegas CM; Latini A; Duval Wannmacher CM; de Souza Wyse AT; Dutra-Filho CS; Wajner M
    Cell Mol Neurobiol; 2007 Feb; 27(1):147-60. PubMed ID: 17151944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kynurenines, neurodegeneration and Alzheimer's disease.
    Kincses ZT; Toldi J; Vécsei L
    J Cell Mol Med; 2010 Aug; 14(8):2045-54. PubMed ID: 20629991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tryptophan metabolism in the central nervous system: medical implications.
    Ruddick JP; Evans AK; Nutt DJ; Lightman SL; Rook GA; Lowry CA
    Expert Rev Mol Med; 2006 Aug; 8(20):1-27. PubMed ID: 16942634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tryptophan metabolism and oxidative stress in patients with Huntington's disease.
    Stoy N; Mackay GM; Forrest CM; Christofides J; Egerton M; Stone TW; Darlington LG
    J Neurochem; 2005 May; 93(3):611-23. PubMed ID: 15836620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.